TD Cowen raised the firm’s price target on Exelixis (EXEL) to $55 from $51 and keeps a Buy rating on the shares. The firm said new combo studies for zanza announced today in NSCLC and mCRPC support expansion strategy but show me story given prior cabo failures.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis Kept at Hold as Cabo Momentum Offsets Pipeline Uncertainty; Price Target Raised from $49 to $50
- Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality
- Analyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases
- Exelixis Posts Strong Q1 Results, Expands Share Buybacks
- EXEL Earnings this Week: How Will it Perform?